ReviewMolecular pathology : MP2001
The IGF/IGFBP system in CNS malignancy.
Review in Molecular pathology : MP, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Mapping naturally presented T cell antigens in medulloblastoma based on integrative multi-omics.Nature communications · 2025Article
- Cytokine profile of cerebrospinal fluid in pediatric patients with metastatic medulloblastoma.Heliyon · 2024Article
- A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma.Neuro-oncology · 2022Article
- miR-4286 is Involved in Connections Between IGF-1 and TGF-β Signaling for the Mesenchymal Transition and Invasion by Glioblastomas.Cellular and molecular neurobiology · 2022Article
- Article
- Bidirectional Enhancement of Cell Proliferation Between Iron Oxide Nanoparticle-Labeled Mesenchymal Stem Cells and Choroid Plexus in a Cell-Based Therapy Model of Ischemic Stroke.International journal of nanomedicine · 2020Article
- Mendelian randomization provides support for obesity as a risk factor for meningioma.Scientific reports · 2019Article
- Type 1 IGF Receptor Localization in Paediatric Gliomas: Significant Association with WHO Grading and Clinical Outcome.Hormones & cancer · 2018Observational
- Secondary Intracranial Tumors Following Radiotherapy for Pituitary Adenomas: A Systematic Review.Cancers · 2017Review
- Estrogen Receptor-β Up-Regulates IGF1R Expression and Activity to Inhibit Apoptosis and Increase Growth of Medulloblastoma.Endocrinology · 2015Article
- Perinatal and familial risk factors for brain tumors in childhood through young adulthood.Cancer research · 2015Article
- Article
- Relationship between concentrations of IGF-1 and IGFBP-3 and preoperative depression risk, and effect of psychological intervention on outcomes of high-grade glioma patients with preoperative depression in a 2-year prospective study.Medical oncology (Northwood, London, England) · 2014Article
- Biomarkers of pediatric brain tumors.Frontiers in pediatrics · 2013Review
- Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates human schwannoma proliferation, adhesion and survival.Oncogene · 2012Article
- Type 2 diabetes mellitus and obesity are independent risk factors for poor outcome in patients with high-grade glioma.Journal of neuro-oncology · 2012Article
- Investigation of immunosuppressive mechanisms in a mouse glioma model.Journal of neuro-oncology · 2009Article
- Biological background of pediatric medulloblastoma and ependymoma: a review from a translational research perspective.Neuro-oncology · 2008Review
- Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials.Current oncology reports · 2008Review
- Neurocytoma is a tumor of adult neuronal progenitor cells.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The insulin-like growth factor (IGF) system includes IGF-I and IGF-II, the type I and type II IGF receptors, and specific IGF binding proteins (IGFBP-1 to IGFBP-6). These factors regulate both normal and malignant brain growth. Enhanced expression of IGF-I and IGF-II mRNA transcripts has been demonstrated in gliomas, meniningiomas, and other tumours. Abnormal imprinting of IGF-II occurs in gliomas, medulloblastomas, and meningiomas. Both types of IGF receptor are expressed in gliomas and, in particular, the type I IGF receptor appears to be upregulated in malignant brain tissue. Antisense IGF-I receptor mRNA induces an antitumour response, resulting in complete brain tumour regression. Clinical trials for the treatment of brain tumours in humans based on a gene transfer protocol using IGF-I receptor antisense are under way. All six IGFBPs are expressed to a variable extent in brain tumours. High concentrations of IGFBP-2 are found in cerebrospinal fluid from patients with malignant central nervous system tumours; therefore, IGFBP-2 might be a useful marker for these tumours. IGFBP-4 appears to be a negative regulator of tumour proliferation. Both in vitro and in vivo experiments suggest that the IGF system represents an important target for the treatment of malignant central nervous system tumours and the ongoing trials should provide valuable information for future therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.